Efficacy and safety of cypropofol combined with low-dose sufentanil sedation in cystoscopy: a randomised controlled trial

Evaluation of the anesthetic effect and safety of ciprofol combined with low-dose sufentanil in painless cystoscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500096071

Enrollment

Unknown

Registered

2025-01-17

Start date

2025-02-01

Completion date

Unknown

Last updated

2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical diseases

Interventions

Cyclopofol group:Ciprofol 0.3mg/kg combined with sufentanil 0.1ug/kg

Propofol group:Propofol 1.5mg/kg combined with sufentanil 0.1ug/kg

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1: ASA Classification I-II; 2: Over 18 years of age and of any gender; 3: Body Mass Index (BMI) 18-30kg/m^2.

Exclusion criteria

Exclusion criteria: 1: severe cardiovascular or pulmonary diseases; 2: sleep apnea syndrome (SAS); 3: a history of renal or hepatic dysfunction; 4: neurocognitive or psychiatric disorders; 5: Known allergies or contraindications to propofol, opioids and ciprofol; 6: possible blocked airway; 7: Patients who refuse to sign informed consent .

Design outcomes

Primary

Measure	Time frame
Induction time of anesthesia;Checking operation time;Anesthesia awakening time;Total duration of anesthesia;Vital signs of each patient at different points in time;	—

Secondary

Measure	Time frame
Number of cases and incidence of adverse cardiovascular events (hypotension, bradycardia), postoperative nausea and vomiting.;	—

Countries

China

Contacts

Public ContactLiao Hongyu

Nanchong Central Hospital

644168670@qq.com+86 176 8323 8130

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026